Based on available recent data from the literature the authors review recent findings pertaining to the etiopathogenesis, immunology, clinical manifestations and treatment of primary gastrointestinal lymphomas. From the pathogenetic aspect in particular the close association with infections and immune disorders in various portions of the gastrointestinal tract is important. In their review the authors draw attention to new aspects of the histological and immunological classification of these tumors, in particular as far as definition of lymphomas of the MALT-system is concerned. They evaluate also data from their own group of 83 patients with regard to the incidence and site of the disease. In the conclusion they draw attention to the importance of some new therapeutic approaches, incl. antibacterial treatment.
Download full-text PDF |
Source |
---|
mSphere
January 2025
Department of Food Science and Technology and Nebraska Food for Health Center, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
Treatment with antibiotics is a major risk factor for infection, likely due to depletion of the gastrointestinal microbiota. Two microbiota-mediated mechanisms thought to limit colonization include the conversion of conjugated primary bile salts into secondary bile salts toxic to growth and competition between the microbiota and for limiting nutrients. Using a continuous flow model that simulates the nutrient conditions of the distal colon, we investigated how treatment with 6 clinically used antibiotics influenced susceptibility to infection in 12 different microbial communities cultivated from healthy individuals.
View Article and Find Full Text PDFTheranostics
January 2025
Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Bone metastasis and skeletal-related complications are primary causes of mortality in advanced-stage prostate cancer (PCa). Epigenetic regulation, particularly histone modification, plays a key role in this process; however, the underlying mechanisms remain elusive. In mouse models, JARID1D was an important mediator of both visceral and bone metastases.
View Article and Find Full Text PDFTransl Cancer Res
December 2024
Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Background: Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest cancers globally. Despite gemcitabine being a primary chemotherapeutic agent, many patients with PDAC develop resistance, significantly limiting treatment efficacy. This study aims to screen and validate key genes associated with gemcitabine resistance in advanced PDAC using bioinformatics analysis and clinical sample validation, thereby providing potential noninvasive biomarkers and therapeutic targets for overcoming chemoresistance.
View Article and Find Full Text PDFEcancermedicalscience
November 2024
National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana.
Background: Cancer is a major public health challenge in West Africa, with a significant proportion of cancer-related deaths attributed to distant metastasis. De novo metastatic cancer (DnMC), where metastasis is detected at diagnosis, presents considerable therapeutic challenges, particularly in limited-resource settings where novel treatments are often unavailable and/or unaffordable.
Aim: To determine the prevalence, incidence and clinicopathological characteristics of patients diagnosed with DnMC at a major radiotherapy center in West Africa.
J Gastrointest Oncol
December 2024
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Background: Classic Hodgkin lymphoma (CHL) is an extremely common non-acquired immunodeficiency syndrome (AIDS) defining malignancy and its incidence is rising. CHL is usually present in the lymph node and extranodal involvement is rare. Primary CHL of the gastrointestinal (GI) tract is exceedingly rare.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!